| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.85.3.928 |
| P698 | PubMed publication ID | 1537129 |
| P2093 | author name string | D. Collen | |
| M. Verstraete | |||
| J. Arnout | |||
| D. de Bono | |||
| F. De Cock | |||
| de Bono D | |||
| H. J. Rapold | |||
| A. E. Arnold | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute myocardial infarction | Q18558122 |
| P304 | page(s) | 928-934 | |
| P577 | publication date | 1992-03-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group | |
| P478 | volume | 85 |
| Q35359038 | Advances in thrombolytic therapy |
| Q70790802 | Changes in circulatory indices of thrombosis and fibrinolysis during total knee arthroplasty performed under tourniquet |
| Q54035550 | Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. |
| Q33495687 | Contemporary use of and future roles for heparin in antithrombotic therapy |
| Q41702106 | Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study |
| Q51057161 | Effect of warfarin withdrawal on thrombolytic treatment in patients with ischaemic stroke. |
| Q56989863 | Engineering of a Staphylokinase-based Fibrinolytic Agent with Antithrombotic Activity and Targeting Capability toward Thrombin-rich Fibrin and Plasma Clots |
| Q73283588 | Enhancing Thrombolysis with Adjunctive Therapy |
| Q74098998 | Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction |
| Q56928597 | Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute Myocardial Infarction |
| Q73286053 | Improving the Efficacy and Stability of Coronary Reperfusion Following Thrombolysis: Exploring the Thrombin Hypothesis |
| Q43942828 | Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction |
| Q33801932 | Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know |
| Q33699831 | Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction |
| Q33671970 | Management of high-risk subsets in unstable angina |
| Q73295821 | Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal |
| Q71024544 | Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy |
| Q73365821 | Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective |
| Q61669298 | Plasma level changes of fibrinopeptide a after uncomplicated coronary angioplasty |
| Q33819693 | The Open-Artery Hypothesis: An Overview |
| Q34376928 | The thrombolytic paradox |
| Q73681259 | Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023) |
| Q56945190 | Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, C |
| Q74322967 | Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty |
| Q77931289 | Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction |
| Q33578384 | Trials of the European Working Party on streptokinase and of the European Cooperative Study Group on alteplase in patients with acute myocardial infarction. European Investigators |
| Q33663297 | Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction |
| Q57798992 | Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction |
Search more.